Articles tagged with: Revlimid

Opinion»

[ by | Apr 15, 2014 10:22 am | 26 Comments ]
Letters From Cancerland: Toxic Dump

Remember Love Canal?

If you came of age in the 1970s or earlier in the United States, you surely re­mem­ber Love Canal.

Love Canal was a neighborhood in Niagara Falls, New York, built atop a chem­i­cal waste dump that had been closed and covered with dirt in the early 1950s. An elementary school was built first, followed soon by the houses.

Even though residents soon started noticing odd smells and oily sub­stances leaching up into the play­ground, it wasn’t until 1976 that the dump, after unusually heavy rains and …

Read the full story »

News»

[ by and | Apr 2, 2014 6:29 pm | 3 Comments ]
Researchers Publish Results Of Revlimid-Velcade-Dexamethasone Trial In Relapsed Multiple Myeloma

Findings from a prospective Phase 2 clinical trial indicate that the com­bi­na­tion of Revlimid, Velcade, and dexamethasone is effective in relapsed and refractory multiple myeloma patients.

The trial enrolled 64 patients, who had been treated with a median of two prior therapies, at six different U.S. cancer centers from 2006 to 2008.

Nearly two-thirds of the patients in the trial achieved at least a partial re­sponse, despite the fact that more than half of the patients had previous­ly been treated with Velcade (bortezomib), and nearly three quarters had …

Read the full story »

News»

[ by and | Mar 7, 2014 5:04 pm | 8 Comments ]
Revlimid And Secondary Cancers: Melphalan May Be The Culprit

The findings of a recent retrospective study may alleviate some of the concerns patients and physicians have had about Revlimid and the risk of secondary cancers.

The study found that the risk of developing a secondary cancer as a result of treatment with Revlimid occurred mainly when a patient had been treated with oral melphalan at the same time as Revlimid.

Revlimid (lenalidomide) did not appear to be associated with an in­creased risk of secondary cancers when administered together with dexamethasone or cyclophosphamide.

In addition, although treatment with …

Read the full story »

News»

[ by and | Mar 5, 2014 8:14 pm | One Comment ]
Revlimid-Dexamethasone Has Mixed Effects On Bone Disease In Relapsed/Refractory Multiple Myeloma

One of the issues that a physician may consider when deciding how to treat a myeloma patient is the impact different treatment options may have on the pa­tient’s bones.

If a patient already has extensive bone damage resulting from multiple myelo­ma, a physician may lean more toward treatments that are believed to halt, or even counteract, the bone destruction the patient has been experiencing.

Previous research has shown that Velcade (bortezomib) may be able to help rebuild the bones of myeloma patients (see related Beacon news).

However, there …

Read the full story »

News»

[ by | Mar 1, 2014 5:56 pm | 2 Comments ]
The Top Myeloma Research Of 2013

The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.

Previous years have witnessed research shedding new light on existing my­e­lo­ma therapies, as well as additional research about potential new therapies.

But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic im­prove­ments in the treat­ment of the disease.

In 2013, not only was there more research about existing therapies, and more …

Read the full story »